Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.75 |
| ▸ | VHL | P40337 | 7/20 | 0.69 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | BCR | P11274 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13408256 | 0.93 | VHL (0.72) | P4HTMVHLABL1BCRNAMPT | |
| SCHEMBL13408249 | 0.93 | P4HTM (0.79) | P4HTMVHLABL1BCRNAMPT | |
| SCHEMBL13408268 | 0.89 | VHL (0.74) | P4HTMVHLNAMPT | |
| SCHEMBL8195975 | 0.88 | P4HTM (0.73) | P4HTMVHLABL1BCRNAMPT | |
| SCHEMBL13408230 | 0.88 | P4HTM (0.79) | P4HTMVHLABL1BCRMEN1 | |
| SCHEMBL13408270 | 0.87 | VHL (0.73) | P4HTMVHLNAMPT | |
| SCHEMBL8183323 | 0.87 | VHL (0.77) | P4HTMVHLNAMPT | |
| SCHEMBL8195131 | 0.86 | P4HTM (1.00) | P4HTMVHL | |
| SCHEMBL13408271 | 0.86 | P4HTM (0.73) | P4HTMVHLNAMPTMEN1KMT2A | |
| SCHEMBL8192905 | 0.86 | P4HTM (0.81) | P4HTMVHL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097404-B1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-07-27 | — | — | EP | disclosed |
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER SCHERRING PHARMA AKTIENGELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER SCHERRING PHARMA AKTIENGELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2008067874-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | DCK, THPO, QDPR | P4HTM 412/4885VHL 25/4885ABL1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.